Keith Alcorn

3 weeks ago | aidsmap.com | Keith Alcorn

Estimated reading time 5 minutes Women with HIV do not have a lower risk of serious heart disease than men, unlike in the rest of the population, an analysis of the REPRIEVE study of statin treatment for people with HIV has found. Moreover, smoking cessation and blood pressure monitoring and management need to be prioritised for all people with HIV at lower risk of serious heart disease, whether or not they choose to take statins.

1 month ago | aidsmap.com | Keith Alcorn

Estimated reading time 5 minutes Young people who have been living with HIV since birth have a significant unmet need for innovative long-acting treatments that can overcome drug resistance and adherence challenges, a London study has concluded. These individuals should be a priority group for inclusion in clinical trials and implementation studies of long-acting treatments, the researchers say.

1 month ago | aidsmap.com | Keith Alcorn

Estimated reading time 8 minutes Semaglutide and related weight-loss medications, known as GLP-1 agonists, may slow biological ageing, reduce inflammation, improve cognitive function and gut health, and reduce alcohol use in people living with HIV, according to studies presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2025).

2 months ago | aidsmap.com | Keith Alcorn

Estimated reading time 4 minutes There have been almost no scientific studies of the effectiveness of HIV pre-exposure prophylaxis (PrEP) in central or eastern Europe. However, a recent study of 887 PrEP users, all gay and bisexual men, in the Polish city of Wroclaw, found only nine HIV infections (1% of PrEP users) over a three-year period from 2020 to 2023. All 887 PrEP users took oral tenofovir disoproxil/emtricitabine (TDF/FTC) pills.

2 months ago | aidsmap.com | Keith Alcorn

Estimated reading time 10 minutes While plans for global access to lenacapavir, the twice-yearly injectable PrEP product which demonstrated extraordinary efficacy last year, have progressed unusually quickly, critics say that the arrangements are riddled with inconsistencies and will not achieve Gilead Science’s stated goals of “ensuring broad, sustainable global access to lenacapavir for PrEP” and of “ending new HIV infections around the world”.